COMMUNIQUÉS West-GlobeNewswire

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences
27/08/2025
THE WOODLANDS, Texas, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at Citi's Biopharma Back to School [...]
FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
27/08/2025
HOUSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of [...]
Disc Medicine to Participate in Upcoming Investor Conferences
27/08/2025
WATERTOWN, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for [...]
Sarborg Limited Closes $10 Million Seed Round to Expand Proprietary Agentic Approach
27/08/2025
Funding supports next-generation AI agent development and proprietary Intellectual Property, focused initially on pharmaceutical drug-repurposing Initial clients reporting commercial success, revolutionizing indication [...]
24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy
27/08/2025
New Peer-Reviewed Publication Highlights Landmark Meeting Co-Sponsored by LIXTE DENVER, Aug. 27, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial [...]
Kailera Therapeutics to Participate in Upcoming Investor Conferences
27/08/2025
WALTHAM, Mass. and SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment [...]
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
27/08/2025
Initial collaboration led to Tyvaso DPI®, the first FDA-approved dry powder inhalation treatment for pulmonary hypertension DANBURY, Conn. and BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD [...]
Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
27/08/2025
Presenting Data from CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma (r/r pHGG) Patients FLORHAM PARK, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cellectar [...]
24/7 Market News: Kraig Labs Prepares for High-Profile International Order as Second Production Facility Reaches Full Operational Status
27/08/2025
Specialized Spider Silk to Fulfill Demand from Iconic Global Brand, Expectations Soar for Q4 Ramp-Up DENVER, Aug. 27, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in digital media dedicated to the swift [...]
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine)
27/08/2025
US Food and Drug Administration (FDA) has granted Fast Track designation for NRX-100 in the treatment of suicidal ideation in patients with depression, including bipolar depression. NRx Pharmaceuticals is making NRX-100 [...]
Emergent BioSolutions to Participate in Upcoming Investor Conferences
27/08/2025
GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences: [...]
Evaxion to present at several conferences during the second half of 2025
27/08/2025
Evaxion will provide scientific and company updates at numerous conferences in both the US, Europe and Asia during the coming months COPENHAGEN, Denmark, August 27, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a [...]
UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®
27/08/2025
BXCL501 achieved SERENITY At-Home’s primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia No discontinuations for tolerability in the [...]
Aclaris Therapeutics to Participate in Two September Healthcare Conferences
27/08/2025
WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
Maxion Therapeutics Strengthens Board with Appointment of Dr. Santiago Arroyo as a Non-Executive Director
27/08/2025
Cambridge, UK, 27 August 2025 – Maxion Therapeutics (“Maxion”), a biotechnology company developing antibody-based KnotBody® drugs for ion channel and G protein coupled receptor (GPCR)-driven diseases, today announces [...]
MIMEDX to Participate in Upcoming Investor Conferences
27/08/2025
MARIETTA, Ga., Aug. 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences [...]
Soleno Therapeutics to Participate in Upcoming September Conferences
27/08/2025
REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced [...]
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
27/08/2025
CARLSBAD, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that [...]
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
27/08/2025
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing [...]

Pages